Phase I/II study of irinotecan and UFT for advanced or metastatic colorectal cancer

R. Mibu, S. Tanaka, K. Futami, K. Shimada, M. Hotokezaka, S. Nakahara, H. Ichimiya, H. Kido, Y. Hirano, T. Kashiwagi, T. Eguchi, K. Mitsuki, K. Mizumoto, M. Tanaka

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The aim of this study was to determine the recommended dose of irinotecan in combination with the fixed dose of oral UFT as first-line therapy inpatients with advanced or recurrent colorectal cancer, and to evaluate the response rate and overall survival as a phase II study. Patients and Methods: Thirteen patients were recruited into a phase I trial. Four doses of irinotecan ranging from 60 to 150 mg/m2/day were administered intravenously on day 1 and day 16 in combination with UFT given orally from day 2 to day 15. In a phase II study, 53 patients received at least one cycle of this therapy. Results: The recommended dose of this combination was determined as irinotecan 120 mg/m 2/day and UFT 400 mg/m2/day. Dose-limiting toxicities were neutropenia and prolonged leucopenia. On an intent-to-treat analysis, the response rate in the phase II study was 24.5% (95% confidence interval 13.8%) to 38.2%). The median overall survival time was 20.3 months (95% confidence interval, 15.0-22.8 months). Out of 20 patients with stable disease, 17 who received more than 4 cycles of the regimen lived longer than the other 3 patients who received fewer than 3 cycles (p=0.0353). Hematological adverse events were mainly grade 3/4 neutropenia observed in 6 out of 53 patients. Grade 3 non-hematological toxicities, such as diarrhea, anorexia, nausea/vomiting and alopecia were observed in 6 patients. Conclusion: Irinotecan combined with oral UFT was effective and well-tolerated. This regimen may be considered as a first-line therapy for advanced or metastatic colorectal cancer and may result in fairly long survival, even for patients with stable disease.

Original languageEnglish
Pages (from-to)2673-2677
Number of pages5
JournalAnticancer research
Volume27
Issue number4 C
Publication statusPublished - Jul 1 2007

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Mibu, R., Tanaka, S., Futami, K., Shimada, K., Hotokezaka, M., Nakahara, S., ... Tanaka, M. (2007). Phase I/II study of irinotecan and UFT for advanced or metastatic colorectal cancer. Anticancer research, 27(4 C), 2673-2677.